Basal Ganglia Diseases
12
3
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
17%
2 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (12)
Study of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Brain-first and Body-first PD
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)
Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands
Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage
The Personalized Parkinson Project De Novo Cohort
Investigating the Neural Signature of Freezing of Gait in Parkinson's Disease
Digital Diagnostics and Intervention Services for Parkinson's Disease
Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease
Intensive Multidisciplinary Rehabilitation and Biomarkers in Parkinson's Disease
Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease
Basal Ganglia Local Field Potentials in Gait and Speech